2009年8月
Clinical significance of serum hepcidin levels on early infectious complications in allogeneic hematopoietic stem cell transplantation.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- 巻
- 15
- 号
- 8
- 開始ページ
- 956
- 終了ページ
- 962
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1016/j.bbmt.2009.04.008
- 出版者・発行元
- ELSEVIER SCIENCE INC
The association of iron overload with complications of allogeneic hematopoietic stem cell transplantation (HSCT) has been suggested in previous studies. Because hepcidin plays a central role in the regulation of iron homeostasis, we analyzed the association between pretransplant serum hepcidin-25 levels and early infectious complications after allogeneic HSCT We studied 55 consecutive adult patients with a median age of 47 years (range: 20-64 years) who underwent allogeneic HSCT for hematologic malignancies at our institution. Thirty-two patients had myelogenous malignancies; the remaining 23 had lymphogenous malignancies. The median pretransplant serum hepcidin level of patients in the study was 21.6 ng/mL (range: 1.4-371 ng/mL), which was comparable to that of healthy volunteers (median: 19.1 ng/mL [range: 2.3-37 ng/mL]; n = 17). When cumulative incidences of documented bacterial and cytomegalovirus (CMV) infections at day 100 were compared according to pretransplant hepcidin-25 levels, the incidence of bacterial, but not CMV, infection, was significantly higher in the high-hepcidin group (= 50 ng/mL; n = 17) than in the low-hepcidin group (<50 ng/mL; n = 38) (65% [95% confidence interval, 38%-82%] versus 11% [3%,23%]; P < .001). This finding was confirmed by multivariate Cox analysis adjusted for confounders, including pretransplant ferritin and C-reactive protein (CRP) levels. No fungal infection was documented in either group. These results suggest that the pretransplant serum hepcidin-25 level may be a useful marker for predicting the risk of early bacterial complications after allogeneic HSCT Larger prospective studies are, however, warranted to confirm our findings. Biol Blood Marrow Transplant 15: 956-962 (2009) (C) 2009,American Society for Blood and Marrow Transplantation
- リンク情報
-
- DOI
- https://doi.org/10.1016/j.bbmt.2009.04.008
- J-GLOBAL
- https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201302265860671784
- PubMed
- https://www.ncbi.nlm.nih.gov/pubmed/19589485
- Web of Science
- https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000268530500008&DestApp=WOS_CPL
- URL
- http://europepmc.org/abstract/med/19589485
- ID情報
-
- DOI : 10.1016/j.bbmt.2009.04.008
- ISSN : 1083-8791
- J-Global ID : 201302265860671784
- ORCIDのPut Code : 24261778
- PubMed ID : 19589485
- Web of Science ID : WOS:000268530500008